Hess H
MMW Munch Med Wochenschr. 1980 Nov 28;122(48):1735-8.
18 years clinical experience with thrombolytic therapy has shown that venous and arterial thrombotic occlusions which persist not only for a few days but also for weeks and 2 to 4 months can be dissolved in about 60-70% of the cases by intravenous infusion of streptokinase. Although this treatment is one of the great break-throughs of internal medicine in this century it is not yet in general use. The reason for this is that the risk of a deleterious bleeding is difficult to assess. This and also the numerous contraindications can be diminished by direct infiltration of an intravasal clot with a relatively small amount of streptokinase through a catheter.
18年的溶栓治疗临床经验表明，静脉和动脉血栓性闭塞不仅持续数天，而且持续数周以及2至4个月，通过静脉输注链激酶，约60% - 70%的病例中的血栓可以溶解。尽管这种治疗是本世纪内科医学的重大突破之一，但尚未得到广泛应用。原因在于有害出血的风险难以评估。通过导管用相对少量的链激酶直接浸润血管内血栓，可以降低这种风险以及众多的禁忌症。
